GSK, Scynexis partner to develop further Brexafemme for fungal infection
Brexafemme is a novel oral glucan synthase inhibitor that works with a distinct mechanism of action where it…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
31 Mar 23
Brexafemme is a novel oral glucan synthase inhibitor that works with a distinct mechanism of action where it…
29 Mar 23
Bicycle Therapeutics will leverage its in-house phage platform to discover bicyclic peptide (Bicycle) to be developed into BRCs,…
21 Mar 23
The collaboration aims to develop and market OncoC4’s monoclonal antibody candidate, ONC-392, as a standalone, or combination therapy…
09 Mar 23
Janssen and its affiliates will get a non-exclusive global license to use Biocytogen’s RenLite platform, and its core…
09 Mar 23
MDX-2201 is ModeX Therapeutics’ preclinical nanoparticle vaccine candidate for Epstein-Barr virus, which is a member of the herpes…
08 Mar 23
The financing, led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly, will support Volastra’s portfolio…
03 Mar 23
Confo's CFTX-1554 is a novel inhibitor of the angiotensin II type 2 receptor (AT2R) intended for the treatment…
24 Feb 23
Capsida will receive $70m, which includes upfront payments and potential equity investment, and is eligible to receive up…
23 Feb 23
The collaboration combines Moderna's mRNA platform with Life Edit's gene editing technologies, including base editing capabilities, to advance…
07 Feb 23
Genetika+ platform allows assessment of the functional effects of drugs directly on human neurons and comprises more than…